Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Endocrine Neoplasia Type 2a 1Medulloblastoma 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 128Carboplatin 127Pemetrexed 107Cisplatin 80Paclitaxel 60osimertinib 55Nivolumab 53Docetaxel 52durvalumab 49Specimen Handling 40Magnetic Resonance Spectroscopy 36Gemcitabine 36Radiosurgery 29atezolizumab 27130-nm albumin-bound paclitaxel 27Cetuximab 26Radiotherapy 23Ipilimumab 22Drug Therapy 22cemiplimab 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Radiation 12Biopsy 12lazertinib 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Vascular Endothelial Growth Factor A × 90 days × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡